Society guideline links: Drug-induced liver injury

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Acute liver failure".)

United States

●American Association for the Study of Liver Diseases (AASLD): Practice guidance on drug, herbal, and dietary supplement-induced liver injury (2023)

●American College of Gastroenterology (ACG): Clinical guideline for the diagnosis and management of idiosyncratic drug-induced liver injury (2021)

●AASLD: Position paper for the management of acute liver failure, update 2011 (published 2012)

●American Thoracic Society (ATS): An official statement on the hepatotoxicity of antituberculosis therapy (2006)

Europe

●European Association for the Study of the Liver (EASL): Clinical practice guidelines on drug-induced liver injury (2019)

●EASL: Clinical practical guidelines on the management of acute (fulminant) liver failure (2017)

India

●Indian National Association for the Study of the Liver (INASL): Consensus statement on acute liver failure (Part 1) – Epidemiology, pathogenesis, presentation, and prognosis (2020)

●INASL: Consensus statement on acute liver failure (Part 2) – Management of acute liver failure (2020)